文献速递泌尿生殖与妇科肿瘤放疗姑息放疗与转移瘤

前列腺放疗对临床淋巴结阳性前列腺癌生存结局的影响:一项多中心回顾性分析

Impact of prostate radiotherapy on survival outcomes in clinically node-positive prostate cancer: A multicentre retrospective analysis.
PubMed 文献 · Radiother Oncol · 2023-06-16

该多中心回顾性分析纳入2011—2019年英国四中心337例影像学cN1M0前列腺癌患者,98.9%接受雄激素剥夺治疗(ADT),70%联合前列腺放疗。中位随访50个月,5年bPFS、rPFS、OS分别为62.7%、71.0%、75.8%。多因素分析显示前列腺放疗与bPFS(HR 0.33)、rPFS(HR 0.25)、OS(HR 0.27)改善独立相关。

要点

  • cN1M0前列腺癌患者中,ADT联合前列腺放疗较未联合者5年bPFS 74.1% vs 34.2%。
  • 联合前列腺放疗者5年rPFS 80.7% vs 44.3%,OS 86.7% vs 56.2%(log rank p<0.001)。
  • 多因素分析前列腺放疗对bPFS的HR 0.33(95%CI 0.18-0.62),对OS的HR 0.27(95%CI 0.13-0.58)。

核心结论

  • 在cN1M0前列腺癌中,ADT联合前列腺放疗较未联合者改善疾病控制和总生存,且独立于其他肿瘤和治疗因素。

研究设计与样本

  • 多中心回顾性分析,纳入2011—2019年英国四中心337例经传统影像学诊断为cN1M0且接受多种模式治疗的前列腺癌男性。

主要发现

  • 337例中47%为Gleason分级组5;98.9%接受ADT,19%单用ADT,70%联合前列腺放疗,38%联合盆腔淋巴结放疗,22%联合多西他赛,7%联合手术。
  • 中位随访50个月,5年bPFS、rPFS、OS分别为62.7%、71.0%、75.8%。
  • 前列腺放疗组 vs 未放疗组5年bPFS 74.1% vs 34.2%,rPFS 80.7% vs 44.3%,OS 86.7% vs 56.2%(log rank p<0.001 each)。
  • 多因素分析(含年龄、Gleason分级组、肿瘤分期、ADT时长、多西他赛、淋巴结放疗)中,前列腺放疗对bPFS的HR 0.33(95%CI 0.18-0.62),对rPFS的HR 0.25(95%CI 0.12-0.51),对OS的HR 0.27(95%CI 0.13-0.58)(p<0.001 each)。
  • 淋巴结放疗或多西他赛的影响因亚组样本量小而未确定。

临床怎么用

  • 原文结论指出,在cN1M0前列腺癌中,ADT联合前列腺放疗较未联合者改善疾病控制和总生存,且独立于其他肿瘤和治疗因素。

局限性

  • 淋巴结放疗或多西他赛的影响因亚组样本量小而未确定。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To evaluate clinical outcomes for cN1M0 prostate cancer treated with varied modalities. MATERIALS AND METHODS: Men with radiological stage cN1M0 prostate cancer on conventional imaging, treated from 2011-2019 with various modalities across four centres in the UK were included. Demographics, tumour grade and stage, and treatment details were collected. Biochemical and radiological progression-free survival (bPFS, rPFS) and overall survival (OS) were estimated using Kaplan Meier analyses. Potential factors impacting survival were tested with univariable log-rank test and multivariable Cox-proportional hazards model. RESULTS: Total 337 men with cN1M0 prostate cancer were included, 47% having Gleason grade group 5 disease. Treatment modalities included androgen deprivation therapy (ADT) in 98.9% men, either alone (19%) or in combinations including prostate radiotherapy (70%), pelvic nodal radiotherapy (38%), docetaxel (22%), or surgery (7%). At median follow up of 50 months, 5-year bPFS, rPFS, and OS were 62.7%, 71.0%, and 75.8% respectively. Prostate radiotherapy was associated with significantly higher bPFS (74.1% vs 34.2%), rPFS (80.7% vs 44.3%) and OS (86.7% vs 56.2%) at five years (log rank p < 0.001 each). On multivariable analysis including age, Gleason grade group, tumour stage, ADT duration, docetaxel, and nodal radiotherapy, benefit of prostate radiotherapy persisted for bPFS [HR 0.33 (95% CI 0.18-0.62)], rPFS [HR 0.25 (0.12-0.51)], and OS [HR 0.27 (0.13-0.58)] (p < 0.001 each). Impact of nodal radiotherapy or docetaxel was not established due to small subgroups. CONCLUSION: Addition of prostate radiotherapy to ADT in cN1M0 prostate cancer yielded improved disease control and overall survival independent of other tumour and treatment factors.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Elumalai T, Maitre P, Portner R, et al. Impact of prostate radiotherapy on survival outcomes in clinically node-positive prostate cancer: A multicentre retrospective analysis. Radiother Oncol. 2023. PMID: 37330057. doi:10.1016/j.radonc.2023.109746

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。